Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water

Authorised

- Spectinomycin sulfate
- Lincomycin hydrochloride

Product identification

Medicine name:
Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water

Active substance:
Spectinomycin sulfate
Lincomycin hydrochloride

Target species:
Pig
Chicken

Route of administration:
Oral use

Product details

Active substance and strength:
Spectinomycin sulfate

575.90 milligram(s) / 1.00 gram(s)

Lincomycin hydrochloride
241.90 milligram(s) / 1.00 gram(s)

Pharmaceutical form:
Powder for use in drinking water

Withdrawal period by route of administration:
Oral use:

- **Pig**
  - Meat and offal. 0 day

Animals must not be slaughtered for human consumption during treatment.

- **Chicken**
  - Meat and offal. 5 day
  - Egg. no withdrawal period

Not for use in birds producing or intended to produce eggs for human consumption

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01FF52

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Cyprus

Package description:
Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 150 g
Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 1.5 kg

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Phibro Animal Health (Poland) Sp. z o.o.

Marketing authorisation date:
27/03/1981

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment

Authorisation number:
7850

Date of authorisation status change:
27/09/2020

Reference member state:
Belgium

Procedure number:
BE/V/0029/001

Concerned member states:
Austria Cyprus Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Poland Portugal Slovakia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 24/03/2026
Download

Package Leaflet

Summary of Product Characteristics